A direct comparison of these immune probes in high-risk and low-risk classifications revealed that KRAS signaling upregulation (| log fold change| = 0.297, adjusted P-value < 0.0001) was the top enriched signature in high-risk ovarian cancer (Figure 3E). The gene discussed is KRAS; the disease is ovarian cancer.